News
Boehringer eyes third quarter FDA verdict for oral HER2 drug
Boehringer Ingelheim's oral HER2 inhibitor zongertinib has started an FDA review as a lung cancer treatment with a decision due in the third quarter.
Sunday 29 June 2025
